{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:01:21Z","timestamp":1791507681320,"version":"4.3.4"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,18]]},"DOI":"10.7759\/cureus.101811","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:18:23Z","timestamp":1768799903000},"source":"Crossref","is-referenced-by-count":1,"title":["An Injection Leading to Oesophageal Perforation: A Rare Case of Contained Boerhaave\u2019s Syndrome Following Unsupervised GLP-1\/GIP Receptor Agonist Dose Escalation"],"prefix":"10.7759","author":[{"given":"Noor Sadiq","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oldfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Akash-Ul-Husnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Moiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min T","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021, 12:143-57. 10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46091","article-title":"Tirzepatide-induced gastrointestinal manifestations: a systematic review and meta-analysis","volume":"15","author":"Karrar HR","year":"2023","unstructured":"Karrar HR, Nouh MI, Nouh YI, et al.. Tirzepatide-induced gastrointestinal manifestations: a systematic review and meta-analysis. Cureus. 2023, 15:e46091. 10.7759\/cureus.46091","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15333","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","volume":"26","author":"Patel H","year":"2024","unstructured":"Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, Rodr\u00edguez \u00c1. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2024, 26:473-81. 10.1111\/dom.15333","journal-title":"Diabetes Obes Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0003-4975(10)63335-8","article-title":"Selective nonoperative management of contained intrathoracic esophageal disruptions","volume":"27","author":"Cameron JL","year":"1979","unstructured":"Cameron JL, Kieffer RF, Hendrix TR, Mehigan DG, Baker RR. Selective nonoperative management of contained intrathoracic esophageal disruptions. Ann Thorac Surg. 1979, 27:404-8. 10.1016\/s0003-4975(10)63335-8","journal-title":"Ann Thorac Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.160.4.8456662","article-title":"Esophageal perforation: CT findings","volume":"160","author":"White CS","year":"1993","unstructured":"White CS, Templeton PA, Attar S. Esophageal perforation: CT findings. AJR Am J Roentgenol. 1993, 160:767-70. 10.2214\/ajr.160.4.8456662","journal-title":"AJR Am J Roentgenol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2003.08.037","article-title":"Evolving options in the management of esophageal perforation","volume":"77","author":"Brinster CJ","year":"2004","unstructured":"Brinster CJ, Singhal S, Lee L, Marshall MB, Kaiser LR, Kucharczuk JC. Evolving options in the management of esophageal perforation. Ann Thorac Surg. 2004, 77:1475-83. 10.1016\/j.athoracsur.2003.08.037","journal-title":"Ann Thorac Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000321","article-title":"GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery","volume":"14","author":"Shankar A","year":"2025","unstructured":"Shankar A, Sharma A, Vinas A, Chilton RJ. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery. Cardiovasc Endocrinol Metab. 2025, 14:e00321. 10.1097\/XCE.0000000000000321","journal-title":"Cardiovasc Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/396771-an-injection-leading-to-oesophageal-perforation-a-rare-case-of-contained-boerhaaves-syndrome-following-unsupervised-glp-1gip-receptor-agonist-dose-escalation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:18:24Z","timestamp":1768799904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/396771-an-injection-leading-to-oesophageal-perforation-a-rare-case-of-contained-boerhaaves-syndrome-following-unsupervised-glp-1gip-receptor-agonist-dose-escalation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.101811","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,18]]}}}